Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, according to CEO David Ricks. This development comes as the company aims to capitalize on the growing demand for obesity treatments.
The pharmaceutical giant is racing against Novo Nordisk, which dominates the market with its injectable medications Zepbound and Wegovy. A weight loss pill would offer more convenience to patients and be easier to manufacture than current injectable forms.
Eli Lilly has reported promising results from orforglipron in mid-stage trials, with patients experiencing a significant weight loss of up to 14.7%, compared to 2.3% for those on a placebo. The company is set to release key late-stage trial data by the middle of this year, further fueling its push to bring the pill to market.
With Eli Lilly and Novo Nordisk struggling to meet soaring demand for their medications, a weight loss pill could be a game-changer. By entering the market early next year, Eli Lilly aims to capture a significant share of the booming weight loss drug market, currently dominated by injectable forms.
Source: https://www.cnbc.com/2025/01/13/eli-lilly-new-weight-loss-pill.html